Clinical Trials Browser

Phase 3 × Plasmacytoma × Dexamethasone × Clear all

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT02544308 2022-12-23

IDRIS

Phase 3 Active not recruiting

Plasmacytoma